Management of renal angiomyolipomas in TSC
mTOR inhibition is likely to transform management of tuberous sclerosis complex and the results of landmark trials are being studied to see if the encouraging reductions in tumour size translate into improved outcomes for patients in the long term
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
More News: Drugs & Pharmacology | Tuberous Sclerosis